Fast Five Quiz: How Much Do You Know About HIV Pre- and Postexposure Prophylaxis?

Jason F. Okulicz, MD


January 19, 2021

PrEP is currently available in nearly 70 countries, and implementation programs are increasing across Europe. In the United States, PrEP is currently available in two combinations approved by the US Food and Drug Administration: TDF/FTC and TAF/FTC. However, TAF/FTC has not been studied in cisgender women, and TDF/FTC is the only combination indicated to prevent HIV acquisition via receptive vaginal intercourse in cisgender women and transgender men.

One concern some researchers and clinicians have regarding the use of PrEP is the potential for drug resistance. Cases of drug resistance have been reported in patients who failed PrEP and were subsequently diagnosed with HIV infection. However, this has mostly been observed in patients whose HIV-positive status was unknown at the time of PrEP initiation or in patients who were nonadherent to PrEP. Because nonadherence is strongly correlated with PrEP failure, it is important that clinicians communicate and reinforce the importance of adherence. Before prescribing PrEP, clinicians should also counsel patients on safer-sex practices to further reduce the risk for sexually transmitted infections (STIs).

Learn more about HIV PrEP.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.